Planned Abscopal Effect with Concurrent Pembrolizumab and Ablative Radiotherapy to Pulmonary Metastasis: A Case Report and Review of the Literature by Yu-Ting Lee, Chien-Chin Chen, Hsiya Chao, Chih-Chia Chang, Cheng-Yen Lee

Subjects: Get full text

Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study by Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara

Subjects: Get full text

The gut microbiota protein BOC1 exhibits immune checkpoint inhibitor-like activity by inhibiting myeloid-derived suppressor cell differentiation by Laureen Bardouillet, Maria Lucia Orsini Delgado, Caroline Matondo, Francesco Strozzi, Valentine Thomas, Laurent Chene, Antonietta Cultrone

Subjects: Get full text

Overexpressed Wnt-7a acts as a potential antitumor immune modulator and predicts poor prognosis in HNSCC by Hui-chao Jiang, Ya Gao, Shu-yan Wang, Yong-lan Zhao, Hai-peng Sun

Subjects: Get full text

EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS by Ahmet Dirican, Safiye Aktaş, Tekincan Aktaş, Aylin Erol, Özde Gökbayrak, Hatice Efsun Kolatan, Efe Özgür Serinan, Zekiye Sultan Altun, Işıl Somalı, Osman Yılmaz

Subjects: Get full text

Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis by Panagiotis T. Diamantopoulos, Aikaterini Gkoufa, Amalia Anastasopoulou, Panagiotis Kouzis, Georgios Lyrarakis, Georgios Kyriakakis, Helen Gogas

Subjects: Get full text

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients by Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto

Subjects: Get full text

Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes by Treshita Dey, Sushma Agrawal

Subjects: Get full text

Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis by Jun Zhao, Xianghua Quan, Yu Liang, Beibei Ni, Xiaomin Xing, Guangwei Liu

Subjects: “…Immune check point inhibitors…”
Get full text

Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication by Blerina Resuli, Diego Kauffmann-Guerrero, Maria Nieves Arredondo Lasso, Jürgen Behr, Amanda Tufman

Subjects: Get full text

Bulk- and single cell-RNA sequencing reveal KIF20A as a key driver of hepatocellular carcinoma progression and immune evasion by Zhixiong Su, Zhixiong Su, Yaqi Zhong, Yufang He, Lijie You, Fuli Xin, Fuli Xin, Lei Wang, Zhihua Liu

Subjects: Get full text

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study by Aida Piedra, Aida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, Teresa Morán, Edurne Arriola, Jordi Recuero-Borau, Manuel Cobo, Patricia Cordeiro, Joaquín Mosquera, Manuel Fernández, Rosario García-Campelo, Antonio Calles, Rosa Álvarez, María Zapata-García, Dolores Isla, Ana Callejo, Patricia Iranzo, Jorgina Serra-López, Andrés Barba, Ivana Sullivan, Enriqueta Felip, Margarita Majem

Subjects: Get full text

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia by Filip Marković, Mihailo Stjepanović, Milan Rančić, Marina Cekić, Milica Kontić

Subjects: Get full text